A phase 3 trial evaluating Pfizer’s quadrivalent modified RNA (modRNA) influenza vaccine candidate has been initiated in the United States.
The quadrivalent modRNA influenza vaccine candidate uses mRNA technology, which requires only the genetic sequence of the virus. This allows for rapid manufacturing that may lead to better strain match and improved protection over current influenza vaccines.
The trial is evaluating the efficacy, safety, tolerability, and immunogenicity of the vaccine candidate in approximately 25,000 healthy US adults. The vaccine candidate will consist of the World Health Organization (WHO) recommended strains for the Northern Hemisphere 2022-2023 cell culture- or recombinant-based influenza vaccines.
“For years, there has been a need to better address the burden of influenza, despite the use of existing seasonal flu vaccines,” said Annaliesa Anderson, PhD, Senior Vice President and CSO, Vaccine Research and Development, Pfizer. “Our experience with RNA viruses and mRNA technology has given us an even deeper understanding of the opportunity to potentially provide more efficacious vaccines that could further reduce the yearly rates of the severe outcomes of viral disease like flu, including hospitalization and death.”
This article originally appeared on MPR
Pfizer initiates phase 3 study of mRNA-based influenza vaccine. News release. Pfizer Inc. Accessed September 14, 2022. https://www.businesswire.com/news/home/20220914005130/en/Pfizer-Initiates-Phase-3-Study-of-mRNA-Based-Influenza-Vaccine